Biohaven Pharma (BHVN) Tops Q4 EPS by 28c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.69), $0.28 better than the analyst estimate of ($2.97). Revenue for the quarter came in at $35.1 million versus the consensus estimate of $28.23 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00